

## Review

**Regulatory T cells in rheumatoid arthritis**Jan Leipe<sup>1</sup>, Alla Skapenko<sup>1</sup>, Peter E Lipsky<sup>2</sup> and Hendrik Schulze-Koops<sup>1,2</sup><sup>1</sup>Nikolaus Fiebiger Center for Molecular Medicine, University of Erlangen-Nuremberg, Erlangen, Germany<sup>2</sup>National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USACorresponding author: Hendrik Schulze-Koops, [schulze-koops@med3.imed.uni-erlangen.de](mailto:schulze-koops@med3.imed.uni-erlangen.de)

Published: 9 March 2005

This article is online at <http://arthritis-research.com/content/7/3/93>

© 2005 BioMed Central Ltd

*Arthritis Research & Therapy* 2005, **7**:93-99 (DOI 10.1186/ar1718)**Abstract**

Apart from the deletion of autoreactive T cells in the thymus, various methods exist in the peripheral immune system to control specific human immune responses to self-antigens. One of these mechanisms involves regulatory T cells, of which CD4<sup>+</sup>CD25<sup>+</sup> T cells are a major subset. Recent evidence suggests that CD4<sup>+</sup>CD25<sup>+</sup> T cells have a role in controlling the development of autoimmune diseases in animals and in humans. The precise delineation of the function of CD4<sup>+</sup>CD25<sup>+</sup> T cells in autoimmune inflammation is therefore of great importance for the understanding of the pathogenesis of autoimmune diseases. Moreover, the ability to control such regulatory mechanisms might provide novel therapeutic opportunities in autoimmune disorders such as rheumatoid arthritis. Here we review existing knowledge of CD4<sup>+</sup>CD25<sup>+</sup> T cells and discuss their role in the pathogenesis of rheumatic diseases.

**Introduction**

The development of autoimmune diseases requires the breakdown of immunologic self-tolerance that usually controls self and non-self discrimination [1]. The primary mechanism that leads to tolerance to self-antigens is the thymic deletion of self-reactive T cells ('negative selection'). However, because some self-reactive T cells escape this process physiologically and autoreactive CD4<sup>+</sup> T cells are present in the peripheral circulation of healthy individuals, where they retain their capacity to initiate autoimmune inflammation [2], negative selection in the thymus is not sufficient to prevent the activation of self-reactive T cells in the periphery [3]. Thus, regulatory mechanisms in the peripheral immune system are required to protect against both the generation of self-directed immune responses and the consequence of this, namely the initiation of autoimmune diseases. It is likely that one such mechanism of peripheral tolerance involves the active suppression of T cell responses by CD4<sup>+</sup> T cells with regulatory capacity, of which a major subset are the CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells.

**Phenotype and function of mouse regulatory T cells**

Regulatory T cells were first discovered in experimental animal models and were subsequently identified in humans. In 1971, a unique subpopulation of T cells was described that was capable of downregulating or suppressing the functions of other cells [4]. These regulatory ('suppressor') T cells had the capacity to transfer antigen-specific tolerance to naive animals. However, the concept of active suppression by T cells lost acceptance because of several technical problems. For example, it was not possible to identify specific cell-surface markers associated with suppressor T cells. Further, when T cell receptor genes were analyzed, suppressor T cells did not seem to have functional gene rearrangements [5]. Most remarkably, soluble suppressor factors, which were believed to be the molecular mechanism of action of suppressor T cells, were thought to be encoded by the murine I-J locus of the major histocompatibility complex (MHC) region. But when molecular studies with hybrid DNA technology failed to identify the I-J region within the MHC [6], the concept of T cell suppression was discarded.

Nevertheless, various experimental observations remained difficult to interpret without postulating an active form of downregulation during an immune response [7]. For many years it was not clear whether distinct specialized T cells exerted this regulatory function or whether this phenomenon was a function of 'non-specialized' T cells. In the mid-1990s a phenotypic description of regulatory T cells eventually became available. Sakaguchi and colleagues [8] showed that injection of CD4<sup>+</sup> T cells from Balb/c mice that had been depleted of the fraction of cells coexpressing CD25 (the IL-2 receptor  $\alpha$ -chain) into athymic Balb/c mice resulted in the development of various organ-specific autoimmune diseases such as thyroiditis, gastritis, colitis and insulin-dependent autoimmune diabetes. Furthermore, co-transfer of CD4<sup>+</sup>CD25<sup>+</sup>

GITR = tumor necrosis factor receptor family-related protein; IFN = interferon; IL = interleukin; JIA = juvenile idiopathic arthritis; MHC = major histocompatibility complex; PBMC = peripheral blood mononuclear cells; RA = rheumatoid arthritis; TGF- $\beta$  = transforming growth factor- $\beta$ ; Treg = regulatory T cell; TNF = tumor necrosis factor.

with the pathogenic CD4<sup>+</sup>CD25<sup>-</sup> T cells prevented the development of experimentally induced autoimmune diseases [9,10]. These data implied that murine CD4<sup>+</sup>CD25<sup>+</sup> T cells are actively able to regulate the responsiveness of auto-reactive T cells that have escaped central tolerance, which distinguishes them from other mechanisms of peripheral tolerance including T cell depletion [11], T cell anergy [12] and immunologic ignorance [13].

CD4<sup>+</sup>CD25<sup>+</sup> T cells are characterized by a low proliferative capacity after triggering with polyclonal or allogeneic stimulation, and by their ability to suppress CD4<sup>+</sup> and CD8<sup>+</sup> immune responses by means of cell-contact dependent mechanisms [14]. CD4<sup>+</sup>CD25<sup>+</sup> T cells have therefore been named regulatory T cells (Tregs). They are typified by the expression of an array of surface molecules, of which several have been implicated in contributing to the suppressive function of Tregs. Although not unique to Tregs, the array of these surface molecules makes it possible to identify Tregs phenotypically. For example, CTLA4 and CD25, which are upregulated on naive and memory T cells after activation, are constitutively expressed on the surface of Tregs. In mice, an important role of CTLA4 in the function of Tregs can be inferred from the ability of CTLA4-specific antibodies to abrogate the CD25<sup>+</sup> T cell-mediated protection of autoimmune gastritis [15] and the CD45RB<sup>low</sup> T cell-mediated inhibition of colitis in the appropriate animal model [16]. However, it is as yet uncertain whether these findings can be explained by the concept that CTLA4 transduces 'negative' signals to activated effector T cells.

Glucocorticoid-induced tumor necrosis factor receptor family-related protein (GITR) is another membrane-associated receptor that was identified during the characterization of the phenotype and function of CD25<sup>+</sup> Tregs [17]. GITR is the specific antigen of an antibody that was generated after immunization with CD25<sup>+</sup> T cells. Although antibodies against GITR abrogate CD25<sup>+</sup>CD4<sup>+</sup> T cell-mediated suppression *in vitro* and *in vivo* [18], the mechanism behind these activities still remains to be determined. However, it should be emphasized that similarly to CD25 and CTLA-4, GITR is not Treg-specific and is upregulated on effector/memory cells after antigen-driven activation. Recently, LAG-3, an MHC class II-binding CD4 homologue was shown to be selectively upregulated on Tregs, and antibodies against LAG-3 inhibited suppression by Tregs, both *in vitro* and *in vivo* [19]. LAG-3 expression remains high on Tregs and decreases shortly after activation in memory T cells, indicating that LAG-3 might mark cells with regulatory activity and is not simply an activation marker. However, it is at present not clear whether LAG-3 selectively marks only certain Treg subsets analyzed in that study.

The transcription factor Foxp3 has been shown to be selectively expressed by Tregs. Foxp3 was first identified as the gene responsible for the defect in scurfy mice, which die

early in life from CD4<sup>+</sup> T cell-mediated lymphoreticular disease, and was subsequently shown to be important in murine Treg development and function [20]. Patients with the IPEX syndrome (for 'immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance'), a clinical syndrome presenting with autoimmune diseases similar to that developing in mice after depletion of CD25<sup>+</sup>CD4<sup>+</sup> regulatory cells, have mutations in Foxp3 [21,22]. This observation provided a first correlation between Tregs and T cell-mediated autoimmune diseases in humans and mice caused by a genetic defect in a defined transcription factor that is essential for the development of the function of Tregs.


However, despite these indications there is still a concern that CD4<sup>+</sup>CD25<sup>+</sup> Tregs from mice that are kept in germ-free facilities with low levels of endogenous T cell activation are not identical with human CD4<sup>+</sup>CD25<sup>+</sup> T cells [23]. In particular, it is at present unclear whether human CD4<sup>+</sup>CD25<sup>+</sup> Tregs are able to suppress immune responses *in vivo*, as their counterparts do in the mouse.

### Phenotype and function of human CD4<sup>+</sup>CD25<sup>+</sup> Tregs

In humans, a population of CD4<sup>+</sup>CD25<sup>+</sup> Tregs has been identified in the peripheral circulation [24-28] and in the thymus [29,30]. In general, the characteristics of human and mouse CD4<sup>+</sup>CD25<sup>+</sup> T cells are very similar. As in mice, 5 to 15% of human peripheral blood CD4<sup>+</sup> T cells constitutively express CD25. It has been proposed that the suppressive effects of human CD4<sup>+</sup>CD25<sup>+</sup> T cells may reside in the CD25<sup>high</sup>CD4<sup>+</sup> T cell fraction [28]; however, this finding is not uniformly accepted [31]. After isolation and *in vitro* allogeneic [25,26], polyclonal [27,29] or antigen-specific [32] stimulation, human CD4<sup>+</sup>CD25<sup>+</sup> T cells do not proliferate – that is, they are anergic [33] – and when cultured with CD4<sup>+</sup>CD25<sup>-</sup> cells, CD4<sup>+</sup>CD25<sup>+</sup> T cells suppress the CD4<sup>+</sup>CD25<sup>-</sup> T cell response in a cell-contact-dependent manner [25] (Fig. 1).

Although CD4<sup>+</sup>CD25<sup>+</sup> cells are unresponsive to mitogenic stimulation, they do proliferate in the presence of exogenous IL-2 [34]. CD4<sup>+</sup>CD25<sup>+</sup> T cells have a differentiated phenotype (CD45RA<sup>-</sup> RO<sup>+</sup> in humans), indicating that they have been stimulated in their internal environment. Evidence suggests that, once these cells are activated, their suppressor function is antigen-nonspecific because CD4<sup>+</sup>CD25<sup>+</sup> Tregs suppress not only T cells stimulated with the same antigens but also T cells activated by other antigens [35]. Thus, Tregs might be able to act as bystander suppressors through contact-dependent mechanisms.

Controversial data exist as to whether and which cytokines are produced by CD4<sup>+</sup>CD25<sup>+</sup> Tregs. Whereas some investigators describe that these cells do not produce immunomodulatory cytokines [28], others demonstrate that they are able to produce IL-10 [27,29,36], transforming

**Figure 1**

Phenotype and function of CD25<sup>+</sup>CD4<sup>+</sup> regulatory T cells from human peripheral blood. **(a)** CD25<sup>+</sup>CD4<sup>+</sup> T cells are anergic. Purified CD25<sup>+</sup> and CD25<sup>-</sup>CD4<sup>+</sup> T cells from the peripheral blood of a healthy individual were stimulated with a monoclonal antibody against CD3, and proliferation was assessed by incorporation of <sup>3</sup>H-labeled thymidine into newly synthesized DNA after 96 hours of culture. **(b)** CD25<sup>+</sup>CD4<sup>+</sup> T cells inhibit the proliferation of autologous peripheral blood mononuclear cells (PBMC). Human PBMC were stimulated with monoclonal antibodies against CD3 in the absence or presence of autologous purified CD25<sup>+</sup> or CD25<sup>-</sup>CD4<sup>+</sup> T cells. Proliferation was assessed as described in (a). **(c)** The regulatory capacity of CD25<sup>+</sup>CD4<sup>+</sup> T cells is inhibited by exogenous IL-2. Human PBMC were stimulated as in (b) in the presence of a non-mitogenic concentration of human IL-2. Proliferation was assessed as in (a). **(d)** Suppression by CD25<sup>+</sup>CD4<sup>+</sup> T cells is contact-dependent and independent of regulatory cytokines. Human PBMC were stimulated with a monoclonal antibody against CD3 in the presence of autologous CD25<sup>+</sup>CD4<sup>+</sup> T cells and neutralizing monoclonal antibodies against IL-10 ( $\alpha$ IL-10) or IL-4 ( $\alpha$ IL-4), or separated from CD25<sup>+</sup>CD4<sup>+</sup> T cells by an insert ('transwell'). Proliferation was assessed as described in (a).

growth factor- $\beta$  (TGF- $\beta$ ) [26,36] and IL-4 [29]. As shown in Fig. 1, however, Tregs exert their inhibitory function independently of the production of potentially immunoregulatory cytokines. Nevertheless, it is widely accepted that Tregs do not produce IL-2.

### CD4<sup>+</sup>CD25<sup>+</sup> Tregs in rheumatoid arthritis

The development of assays to evaluate the function of human CD4<sup>+</sup>CD25<sup>+</sup> Tregs *in vitro* has provided the opportunity to analyze the role of Tregs in human autoimmune diseases such as rheumatoid arthritis (RA). A series of recent articles has focused on the role of Tregs in rheumatoid inflammation and has indicated that CD4<sup>+</sup>CD25<sup>+</sup> T cells might function as potential regulators of immune responses in RA.

### Phenotype of peripheral blood CD4<sup>+</sup>CD25<sup>+</sup> T cells in RA


Controversy exists with regard to the frequency of CD4<sup>+</sup>CD25<sup>+</sup> T cells in the peripheral circulation of patients with RA in comparison with healthy individuals [31,37,38]. The divergent results might be in part related to different definitions of CD4<sup>+</sup>CD25<sup>+</sup> T cells, because some investigators focused on the CD25<sup>bright</sup> T cells [39], whereas others analyzed the total population of CD25<sup>+</sup> T cells [31]. In patients with a different but related inflammatory joint disease, juvenile idiopathic arthritis (JIA), the frequency of CD25<sup>bright</sup>CD4<sup>+</sup> cells in the peripheral blood was lower than in healthy controls [40]. Patients with a self-limiting form of JIA had an increased frequency of CD25<sup>bright</sup>CD4<sup>+</sup> T cells with higher levels of FoxP3 mRNA in the peripheral blood than in patients with the subtype of the disease with a less

favorable prognosis, suggesting a functional role for CD25<sup>bright</sup>CD4<sup>+</sup> T cells in JIA. Although it is difficult to transfer the findings from one inflammatory joint disease to another, JIA and RA are related in their mechanisms of disease pathogenesis and their clinical presentation, suggesting that the findings in JIA might at least in part represent the situation in RA adequately.

A significant correlation was found between the frequency of CD4<sup>+</sup>CD25<sup>+</sup> T cells in the peripheral blood of patients with RA, the erythrocyte sedimentation rate [31] and the level of C-reactive protein [38], which suggests that in active disease the frequency of CD4<sup>+</sup>CD25<sup>+</sup> T cells increases. In contrast, no associations were detected between the frequency of CD4<sup>+</sup>CD25<sup>+</sup> T cells in the peripheral blood and the use of methotrexate, corticosteroids or tumor necrosis factor (TNF)-neutralizing agents [31,37]. However, in a subsequent study a significant increase in the number of CD4<sup>+</sup>CD25<sup>high</sup> T cells was observed after anti-TNF treatment in patients with RA [38] who responded to therapy, but not in those patients who failed to respond to therapy.

### Phenotype of synovial CD4<sup>+</sup>CD25<sup>+</sup> T cells in RA

In contrast to the situation in the peripheral blood, there is clear evidence that the frequencies of CD4<sup>+</sup>CD25<sup>+</sup> T cells in the synovial fluid of patients with RA are elevated compared with those in the peripheral blood (Fig. 2) [31,39]. CD25<sup>bright</sup>CD4<sup>+</sup> T cells are enriched in the synovial fluid not only in patients with RA but also in patients with spondylarthropathies or with JIA [37,40].

**Figure 2**

CD25<sup>+</sup>CD4<sup>+</sup> T cells are enriched in the synovial fluid in rheumatoid arthritis. Mononuclear cells were isolated from the peripheral blood (PB) or the synovial fluid (SF) of a patient with rheumatoid arthritis, stained with monoclonal antibodies against CD4 and CD25 and analyzed by flow cytometry. The numbers denote the frequency of cells in the gate as defined by the expression of CD4 and CD25.

Several alternative mechanisms might contribute to the enrichment of CD4<sup>+</sup>CD25<sup>+</sup> T cells in the synovial fluid of patients with rheumatic diseases. A preferential migration of these cells into the inflamed joint might be inferred from the observation that CD4<sup>+</sup>CD25<sup>+</sup> T cells specifically express the chemokine receptors CXCR4, CCR4 and CCR8 [41]. The CCR4 ligands CCL17 and CCL22 are highly expressed in synovial tissue [42], and it has been suggested that dendritic cells are able to 'chemoattract' cells by the secretion of CCL17 and CCL22 [41]. However, it should be pointed out that although CCR4<sup>+</sup> T cells can be detected in the peripheral blood of healthy individuals and in the synovial fluid of patients with RA, the vast majority of T cells in the rheumatoid synovial fluid do not express CCR4 [43], making the CCR4–CCL17-mediated recruitment of Tregs into the rheumatoid joint rather unlikely. The ligand for CXCR4, stromal-derived factor-1 (SDF-1), is expressed on synovial endothelial cells [44], and persistent expression of the chemokine receptor CXCR4 on synovial CD4 T cells mediates their active retention within the rheumatoid synovium [45]. Because human CD4<sup>+</sup>CD25<sup>+</sup> Tregs traffic to and are retained in the bone marrow through interactions involving CXCR4 [46], it is also conceivable that CD4<sup>+</sup>CD25<sup>+</sup> T cells are selectively recruited to and retained in the rheumatoid joint through interactions involving CXCR4. In line with the hypothesis that CD4<sup>+</sup>CD25<sup>+</sup> T cells are effectively recruited to sites of chronic inflammation, CD25<sup>+</sup>CD4<sup>+</sup> T cells are found in inflammatory infiltrates of C57BL/6 mice infected with *Leishmania major* [47] and of Balb/c mice infected with *Candida albicans* [48]. The data therefore suggest that the accumulation of CD4<sup>+</sup>CD25<sup>+</sup> T cells during an inflammatory immune response might be a physiologic control mechanism of potentially dangerous effector functions to prevent tissue damage.

A second mechanism leading to the accumulation of CD4<sup>+</sup>CD25<sup>+</sup> T cells in the rheumatic joint might relate to the fact that inflammatory cytokines such as IL-2 and costimulatory molecules cause CD4<sup>+</sup>CD25<sup>+</sup> T cells to revert to an anergic phenotype [34] (Fig. 1c). Because the synovial fluid contains high levels of inflammatory cytokines and of antigen-presenting cells that are able to engage costimulatory molecules on synovial T cells, CD25<sup>+</sup>CD4<sup>+</sup> T cells might expand locally in the rheumatoid joint. However, in the rheumatoid synovium it was found that T cells display low proliferative responses [49], and in patients with JIA the T cells in the synovial fluid are not actively dividing [50].

A third alternative method for the enrichment of CD4<sup>+</sup>CD25<sup>+</sup> T cells in the rheumatoid joint is related to the observation that synovial T cells are actively inhibited from undergoing apoptosis, thereby expanding their lifespan compared with their peripheral counterparts. An integrin–ligand interaction is involved in the fibroblast-mediated survival of synovial T cells [51]. Fibroblast-secreted IFN- $\beta$  is also able to inhibit apoptosis, and in particular that of CD4<sup>+</sup>CD25<sup>+</sup> T cells [24].

A final explanation for the increased frequencies of CD25<sup>+</sup> T cells in the synovium derives from the characteristic of CD25 to be upregulated on activated T cells. Thus, the sole determination of CD25 does not make it possible to discriminate Tregs from activated effector cells. Because synovial T cells express an array of activation markers and effector functions, it is likely that most CD25-expressing T cells from the synovial fluid constitute an effector population actively engaged in driving synovial inflammation.

Recent evidence suggests that the CD4<sup>+</sup>CD25<sup>+</sup> Tregs from the synovial fluid are different from those in the peripheral circulation. CD25<sup>bright</sup>CD4<sup>+</sup> T cells from the synovial fluid in RA contain higher frequencies of cells expressing CTLA-4 and GITR than those from the peripheral blood of healthy donors and of patients with RA [31,37]. Tregs from synovial fluid also display an activated phenotype with a higher expression of CD69 and MHC class II than CD4<sup>+</sup>CD25<sup>+</sup> cells in the peripheral blood of matched individuals.

Intermittent flares in disease activity are typical of RA. Whether the frequency of regulatory CD25<sup>bright</sup>CD4<sup>+</sup> T cells fluctuate over time or are correlated with disease activity is therefore of considerable interest. Although the frequency of synovial CD25<sup>bright</sup>CD4<sup>+</sup> T cells varies between patients, the numbers of these cells do not vary significantly over time in a single joint [39]. Similar stable frequencies of synovial CD25<sup>bright</sup>CD4<sup>+</sup> T cells over time were also observed in patients with JIA, psoriatic arthritis and spondylarthropathies [37]. Moreover, the frequencies of synovial CD25<sup>bright</sup>CD4<sup>+</sup> T cells in patients with RA was not correlated with clinical parameters such as disease duration, the presence of rheumatoid factor, the level of C-reactive protein and the presence of erosions [31,37]. In addition, no association was

found between the use of methotrexate, corticosteroids or anti-TNF therapy and the frequency of CD4<sup>+</sup>CD25<sup>+</sup> T cells in the synovial fluid [31]. These data suggest that the presence of CD4<sup>+</sup>CD25<sup>+</sup> T cells in the rheumatoid synovium is a function of the disease and is characteristic of a particular patient but unrelated to treatment, clinical course and disease activity. These results might therefore question the importance of CD4<sup>+</sup>CD25<sup>+</sup> Tregs in the regulation of synovial inflammation.

Together, the data suggest that CD4<sup>+</sup>CD25<sup>+</sup> T cells in chronically inflamed rheumatoid joints might enrich and persist as a result of preferential recruitment, rescue from cell death and activation by their specific antigen. Consequently, the determination of frequencies of CD25<sup>+</sup> T cells in the synovial fluid without complementary functional studies does not make it possible to draw meaningful conclusions about the role of CD4<sup>+</sup>CD25<sup>+</sup> Tregs in rheumatoid inflammation.

### Function of synovial CD4<sup>+</sup>CD25<sup>+</sup> T cells in RA

When examined in conventional *in vitro* assays, synovial CD4<sup>+</sup>CD25<sup>bright</sup> T cells are able to suppress the proliferation of autologous CD4<sup>+</sup>CD25<sup>-</sup> (responder) T cells of synovial and peripheral origin [31,37,39]. Synovial CD4<sup>+</sup>CD25<sup>+</sup> T cells display an even increased suppressive capacity compared with blood CD4<sup>+</sup>CD25<sup>+</sup> T cells in RA [31] and in JIA [40]. It is of interest that CD4<sup>+</sup>CD25<sup>intermediate</sup> T cells enhance rather than suppress the proliferation of synovial responder CD4<sup>+</sup>CD25<sup>-</sup> T cells, which might suggest that CD25<sup>intermediate</sup> T cells represent effector T cells.

The major question that these results immediately bring up is why inflammation occurs in the rheumatoid joints despite elevated frequencies of apparently functional CD4<sup>+</sup>CD25<sup>+</sup> T cells with an even enhanced suppressive capacity in assays *in vitro*.

One possible explanation for this seeming paradox might be an active inhibition of the function of Tregs in the rheumatoid joint. For example, several constituents of the inflamed synovial environment, such as IL-2 and IL-7, have been shown to abrogate the function of Tregs [34,52], suggesting that Tregs are inhibited at sites of inflammation from performing their regulatory function by pro-inflammatory cytokines. Similarly, although shown only for peripheral blood, it has been suggested that CD4<sup>+</sup>CD25<sup>+</sup> T cells display functional differences before and after treatment with anti-TNF [38]. CD4<sup>+</sup>CD25<sup>high</sup> cells isolated from the peripheral blood of patients with active RA suppress the proliferative response of responder CD4<sup>+</sup> T cells but not the secretion of inflammatory cytokines such as IFN- $\gamma$  and TNF. In contrast, CD4<sup>+</sup>CD25<sup>high</sup> cells isolated from the patients' blood after anti-TNF therapy suppress (like CD4<sup>+</sup>CD25<sup>high</sup> cells in healthy individuals) not only the proliferation but also the secretion of these cytokines from responder CD4<sup>+</sup> T cells derived from anti-TNF-treated patients. Thus, these findings indicate a functional deficit of

CD4<sup>+</sup>CD25<sup>high</sup> T cells from patients with active RA with regard to their ability to suppress pro-inflammatory cytokine production that reverts after treatment with TNF-neutralizing agents. Additional evidence for an inhibitory function of TNF on Tregs in RA derives from experiments in which the depletion of CD4<sup>+</sup>CD25<sup>high</sup> T cells from peripheral blood mononuclear cells (PBMC) from patients with active RA did not alter the frequency of cells producing TNF or IL-10 in a 2-day cell culture, whereas an increase in TNF-secreting cells and a reduction in IL-10-secreting cells occurred in the culture of PBMC derived from anti-TNF-treated patients with RA that were depleted of Tregs [38]. Together, these data might underline the potential role of cytokines in maintaining chronic inflammation *in vivo*.

An alternative explanation for persistent synovial inflammation despite enriched numbers of CD4<sup>+</sup>CD25<sup>+</sup> T cells with enhanced suppressive capacity *in vitro* is provided by the finding that synovial responder T cells express a decreased susceptibility to the regulatory effect of CD4<sup>+</sup>CD25<sup>+</sup> Tregs in comparison with peripheral blood responder T cells, thereby 'compensating' for the enhanced regulatory capacity of the synovial Tregs [31]. IL-6, which is known to be found in large amounts in the rheumatoid synovium [53], has been shown to enhance the resistance of T effector cells to the suppressive effects of Tregs [54]. Finally, although suppression by Tregs is probably not antigen-specific but might involve neighboring T cells in a 'bystander' fashion [35], Tregs require activation through their T-cell antigen receptor to deliver their regulatory function. Thus, if the specific antigen for the synovial Tregs is not presented either in the secondary lymphoid organs or in the inflamed synovia, or, alternatively, if Tregs in RA express an altered threshold for antigen-specific activation, synovial Tregs, although present, will not become activated and will therefore fail to inhibit ongoing inflammation.

Together, these arguments indicate that rheumatoid inflammation occurs in the presence of Tregs that express an impaired regulatory function *in vivo*, despite their enhanced regulatory capacity *in vitro*. Although it is tempting to speculate that synovial inflammation is the consequence of an inadequate ability of synovial Tregs to downmodulate local inflammation, several observations indicate clearly that synovial Tregs are functional and actively dampen the inflammatory immune response *in vivo*. For example, in JIA the frequencies of CD4<sup>+</sup>CD25<sup>+</sup> synovial T cells are inversely correlated with the clinical outcome, and the expression of FoxP3 mRNA, a 'marker' for Treg function, is elevated in mild cases in comparison with severe forms of the disease [50]. In collagen-induced arthritis, depletion of CD4<sup>+</sup>CD25<sup>+</sup> T cells accelerates the onset of severe disease, and transfer of syngeneic CD4<sup>+</sup>CD25<sup>+</sup> T cells into Treg-depleted mice reverses the increased severity [55]. Thus, the local expansion in the CD4<sup>+</sup>CD25<sup>+</sup> Treg cell population in the rheumatoid synovium might reflect a mechanism for resolving the inflammatory immune response. Although not sufficient to

prevent inflammatory activity in the joint, the CD4<sup>+</sup>CD25<sup>+</sup> Tregs in the inflamed rheumatoid synovium might nevertheless be important for a downmodulation of the inflammation, thereby delaying further tissue damage and impeding erosive inflammation. These findings might be of relevance in validating and fostering the development of clinical applications of *in vitro*-generated Tregs in autoimmune diseases in the near future by means of personalized cellular therapy.

It should be noted that other subsets of CD4 T cells have been identified that are capable of suppressing specific immune responses. The most prominent of these are termed Treg 1 (Tr1) and T helper type 3 (Th3) cells. Th3 cells produce predominantly TGF- $\beta$ . They are generated *in vivo* by immunization through an oral or other mucosal route [35], and have been detected in patients with multiple sclerosis after oral administration of myelin basic protein [56]. Groux and colleagues first isolated mouse and human Tr1 cells that have immune-regulatory activities both *in vitro* and *in vivo* [57,58]. These regulatory CD4<sup>+</sup> T cells secrete IL-10 and have been generated *in vitro* by repeated antigenic stimulations of human and murine CD4<sup>+</sup> cells in the presence of IL-10 [26,59,60] or by activation through immature antigen-presenting cells that lack potent costimulatory activity [61].

However, comprehensive analyses of Tr1 and Th3 cells in humans are not available, so the precise role of these subsets in human autoimmune disease has not been defined.

## Conclusions

In conclusion, human CD4<sup>+</sup>CD25<sup>+</sup> Tregs that are capable of suppressing CD4 T cell proliferation *in vitro* are enriched in the synovial fluid of patients with RA. Synovial Tregs express an increased regulatory capacity in comparison with Tregs derived from the peripheral blood, in assays *in vitro*. In the synovium, Tregs might be inhibited by different mechanisms such as inflammatory cytokines including TNF, or stimulation by antigen-presenting cells, which in concert might allow synovial inflammation to evolve and persist despite the enhanced frequencies of synovial Tregs. However, because evidence suggests that synovial Tregs, although not sufficient to ameliorate disease activity completely, are involved in regulating synovial inflammation *in vivo*, future treatment strategies of autoimmune diseases can be envisaged in which Tregs generated and/or expanded *in vitro* will be employed in an attempt to control local and systemic autoimmune inflammation.

## Competing interests

The author(s) declare that they have no competing interests.

## Acknowledgments

This work was supported in part by the Deutsche Forschungsgemeinschaft (Grants Schu 786/2-3 and 2-4) and by the Interdisciplinary Center for Clinical Research (IZKF) at the University hospital of the University of Erlangen-Nuremberg (Projects B27 and B3).

## References

- Bach JF, Chatenoud L: **Tolerance to islet autoantigens in type 1 diabetes.** *Annu Rev Immunol* 2001, **19**:131-161.
- Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA: **T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis.** *Nature* 1990, **346**:183-187.
- Sakaguchi S: **Regulatory T cells: key controllers of immunologic self-tolerance.** *Cell* 2000, **101**:455-458.
- Gershon RK, Kondo K: **Infectious immunological tolerance.** *Immunology* 1971, **21**:903-914.
- Hedrick SM, Germain RN, Bevan MJ, Dorf M, Engel I, Fink P, Gascoigne N, Heber-Katz E, Kapp J, Kaufmann Y, *et al.*: **Rearrangement and transcription of a T-cell receptor beta-chain gene in different T-cell subsets.** *Proc Natl Acad Sci USA* 1985, **82**:531-535.
- Kronenberg M, Steinmetz M, Kobori J, Kraig E, Kapp JA, Pierce CW, Sorensen CM, Suzuki G, Tada T, Hood L: **RNA transcripts for I-J polypeptides are apparently not encoded between the I-A and I-E subregions of the murine major histocompatibility complex.** *Proc Natl Acad Sci USA* 1983, **80**:5704-5708.
- Janeway CA Jr: **Do suppressor T cells exist? A reply.** *Scand J Immunol* 1988, **27**:621-623.
- Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: **Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.** *J Immunol* 1995, **155**:1151-1164.
- McHugh RS, Shevach EM: **Cutting edge: depletion of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease.** *J Immunol* 2002, **168**:5979-5983.
- Mottet C, Uhlig HH, Powrie F: **Cutting edge: cure of colitis by CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells.** *J Immunol* 2003, **170**:3939-3943.
- Miller JF, Basten A: **Mechanisms of tolerance to self.** *Curr Opin Immunol* 1996, **8**:815-821.
- Schwartz RH: **Models of T cell anergy: is there a common molecular mechanism?** *J Exp Med* 1996, **184**:1-8.
- Miller JF, Heath WR: **Self-ignorance in the peripheral T-cell pool.** *Immunol Rev* 1993, **133**:131-150.
- Thornton AM, Shevach EM: **Suppressor effector function of CD4<sup>+</sup>CD25<sup>+</sup> immunoregulatory T cells is antigen nonspecific.** *J Immunol* 2000, **164**:183-190.
- Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S: **Immunologic self-tolerance maintained by CD25<sup>+</sup>CD4<sup>+</sup> regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.** *J Exp Med* 2000, **192**:303-310.
- Read S, Malmstrom V, Powrie F: **Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25<sup>+</sup>CD4<sup>+</sup> regulatory cells that control intestinal inflammation.** *J Exp Med* 2000, **192**:295-302.
- McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, Byrne MC: **CD4<sup>+</sup>CD25<sup>+</sup> immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor.** *Immunity* 2002, **16**:311-323.
- Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S: **Stimulation of CD25<sup>+</sup>CD4<sup>+</sup> regulatory T cells through GITR breaks immunological self-tolerance.** *Nat Immunol* 2002, **3**:135-142.
- Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI, *et al.*: **Role of LAG-3 in regulatory T cells.** *Immunity* 2004, **21**:503-513.
- Hori S, Nomura T, Sakaguchi S: **Control of regulatory T cell development by the transcription factor Foxp3.** *Science* 2003, **299**:1057-1061.
- Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD: **The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3.** *Nat Genet* 2001, **27**:20-21.
- Gambineri E, Torgerson TR, Ochs HD: **Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis.** *Curr Opin Rheumatol* 2003, **15**:430-435.
- Baecher-Allan C, Hafler DA: **Suppressor T cells in human diseases.** *J Exp Med* 2004, **200**:273-276.

24. Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN: **Human anergic/suppressive CD4<sup>+</sup>CD25<sup>+</sup> T cells: a highly differentiated and apoptosis-prone population.** *Eur J Immunol* 2001, **31**:1122-1131.
25. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH: **Identification and functional characterization of human CD4<sup>+</sup>CD25<sup>+</sup> T cells with regulatory properties isolated from peripheral blood.** *J Exp Med* 2001, **193**:1285-1294.
26. Levings MK, Sangregorio R, Roncarolo MG: **Human CD25<sup>+</sup>CD4<sup>+</sup> T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function.** *J Exp Med* 2001, **193**:1295-1302.
27. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G: **Ex vivo isolation and characterization of CD4<sup>+</sup>CD25<sup>+</sup> T cells with regulatory properties from human blood.** *J Exp Med* 2001, **193**:1303-1310.
28. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA: **CD4<sup>+</sup>CD25<sup>+</sup>high regulatory cells in human peripheral blood.** *J Immunol* 2001, **167**:1245-1253.
29. Stephens LA, Mottet C, Mason D, Powrie F: **Human CD4<sup>+</sup>CD25<sup>+</sup> thymocytes and peripheral T cells have immune suppressive activity in vitro.** *Eur J Immunol* 2001, **31**:1247-1254.
30. Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vanini V, Romagnani P, Maggi E, Romagnani S: **Phenotype, localization, and mechanism of suppression of CD4<sup>+</sup>CD25<sup>+</sup> human thymocytes.** *J Exp Med* 2002, **196**:379-387.
31. van Amelsfort JM, Jacobs KM, Bijlsma JW, Lafeber FP, Taams LS: **CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid.** *Arthritis Rheum* 2004, **50**:2775-2785.
32. Taams LS, Vukmanovic-Stejić M, Smith J, Dunne PJ, Fletcher JM, Plunkett FJ, Ebeling SB, Lombardi G, Rustin MH, Bijlsma JW, et al.: **Antigen-specific T cell suppression by human CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells.** *Eur J Immunol* 2002, **32**:1621-1630.
33. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH: **Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.** *J Immunol* 2002, **168**:4272-4276.
34. Thornton AM, Shevach EM: **CD4<sup>+</sup>CD25<sup>+</sup> immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production.** *J Exp Med* 1998, **188**:287-296.
35. Weiner HL: **Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells.** *Microbes Infect* 2001, **3**:947-954.
36. Nakamura K, Kitani A, Strober W: **Cell contact-dependent immunosuppression by CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells is mediated by cell surface-bound transforming growth factor beta.** *J Exp Med* 2001, **194**:629-644.
37. Cao D, van Vollenhoven R, Klareskog L, Trollmo C, Malmstrom V: **CD25<sup>bright</sup>CD4<sup>+</sup> regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease.** *Arthritis Res Ther* 2004, **6**:R335-346.
38. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C: **Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF $\alpha$  therapy.** *J Exp Med* 2004, **200**:277-285.
39. Cao D, Malmstrom V, Baecher-Allan C, Hafler D, Klareskog L, Trollmo C: **Isolation and functional characterization of regulatory CD25<sup>bright</sup>CD4<sup>+</sup> T cells from the target organ of patients with rheumatoid arthritis.** *Eur J Immunol* 2003, **33**:215-223.
40. de Kleer IM, Wedderburn LR, Taams LS, Patel A, Varsani H, Klein M, de Jager W, Pugayung G, Giannoni F, Rijkers G, et al.: **CD4<sup>+</sup>CD25<sup>bright</sup> regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis.** *J Immunol* 2004, **172**:6435-6443.
41. Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, Sinigaglia F, D'Ambrosio D: **Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells.** *J Exp Med* 2001, **194**:847-853.
42. Radstake TR, Van Der Voort R, Ten Brummelhuis M, De Waal Malefijt M, Schreurs W, Looman M, Sloetjes A, Figdor CG, Van Den Berg WB, Barrera P, et al.: **Increased expression of CCL18, CCL19, and CCL17 by dendritic cells from patients with rheumatoid arthritis and regulation by Fc gamma receptors.** *Ann Rheum Dis* 2004.
43. Suzuki N, Nakajima A, Yoshino S, Matsushima K, Yagita H, Okumura K: **Selective accumulation of CCR5<sup>+</sup> T lymphocytes into inflamed joints of rheumatoid arthritis.** *Int Immunol* 1999, **11**:553-559.
44. Buckley CD, Amft N, Bradfield PF, Pilling D, Ross E, Arenzana-Seisdedos F, Amara A, Curnow SJ, Lord JM, Scheel-Toellner D, et al.: **Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium.** *J Immunol* 2000, **165**:3423-3429.
45. Nanki T, Hayashida K, El-Gabalawy HS, Suson S, Shi K, Girschick HJ, Yavuz S, Lipsky PE: **Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4<sup>+</sup> T cell accumulation in rheumatoid arthritis synovium.** *J Immunol* 2000, **165**:6590-6598.
46. Zou L, Barnett B, Safah H, Larussa VF, Evdemon-Hogan M, Mottram P, Wei S, David O, Curiel TJ, Zou W: **Bone marrow is a reservoir for CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells that traffic through CXCL12/CXCR4 signals.** *Cancer Res* 2004, **64**:8451-8455.
47. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL: **CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells control *Leishmania major* persistence and immunity.** *Nature* 2002, **420**:502-507.
48. Montagnoli C, Bacci A, Bozza S, Gaziano R, Mosci P, Sharpe AH, Romani L: **B7/CD28-dependent CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells are essential components of the memory-protective immunity to *Candida albicans*.** *J Immunol* 2002, **169**:6298-6308.
49. Petersen J, Andersen V, Ingemann-Hansen T, Halkjaer-Kristensen J, Wiik A, Thyssen H: **Synovial fluid and blood monocyte influence on lymphocyte proliferation in rheumatoid arthritis and traumatic synovitis.** *Scand J Rheumatol* 1983, **12**:299-304.
50. Black AP, Bhayani H, Ryder CA, Gardner-Medwin JM, Southwood TR: **T-cell activation without proliferation in juvenile idiopathic arthritis.** *Arthritis Res* 2002, **4**:177-183.
51. Salmon M, Scheel-Toellner D, Huissoon AP, Pilling D, Shamsadeen N, Hyde H, D'Angeac AD, Bacon PA, Emery P, Akbar AN: **Inhibition of T cell apoptosis in the rheumatoid synovium.** *J Clin Invest* 1997, **99**:439-446.
52. van Amelsfort JM, Noordegraaf M, Bijlsma JWJ, Taams LS, Lafeber FPJG: **Influence of the inflammatory milieu on the suppressive function of CD4<sup>+</sup>CD25<sup>+</sup> T cells in rheumatoid arthritis.** *Arthritis Rheum* 2004, **50**:S526.
53. Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, Sato K, Shimizu M, Maini R, Feldmann M, et al.: **Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis.** *Eur J Immunol* 1988, **18**:1797-1801.
54. Pasare C, Medzhitov R: **Toll pathway-dependent blockade of CD4<sup>+</sup>CD25<sup>+</sup> T cell-mediated suppression by dendritic cells.** *Science* 2003, **299**:1033-1036.
55. Morgan ME, Suttmuller RP, Witteveen HJ, van Duivenvoorde LM, Zanelli E, Melief CJ, Srijders A, Offringa R, de Vries RR, Toes RE: **CD25<sup>+</sup> cell depletion hastens the onset of severe disease in collagen-induced arthritis.** *Arthritis Rheum* 2003, **48**:1452-1460.
56. Fukaura H, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler DA: **Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients.** *J Clin Invest* 1996, **98**:70-77.
57. Groux H, Bigler M, de Vries JE, Roncarolo MG: **Interleukin-10 induces a long-term antigen-specific anergic state in human CD4<sup>+</sup> T cells.** *J Exp Med* 1996, **184**:19-29.
58. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG: **A CD4<sup>+</sup> T-cell subset inhibits antigen-specific T-cell responses and prevents colitis.** *Nature* 1997, **389**:737-742.
59. Asseman C, Powrie F: **Interleukin 10 is a growth factor for a population of regulatory T cells.** *Gut* 1998, **42**:157-158.
60. Cottrez F, Hurst SD, Coffman RL, Groux H: **T regulatory cells 1 inhibit a Th2-specific response in vivo.** *J Immunol* 2000, **165**:4848-4853.
61. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH: **Induction of interleukin 10-producing, nonproliferating CD4<sup>+</sup> T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells.** *J Exp Med* 2000, **192**:1213-1222.